{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:25:18Z","timestamp":1753892718452,"version":"3.41.2"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T00:00:00Z","timestamp":1581465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"DOI":"10.3389\/fpsyt.2020.00032","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T04:43:47Z","timestamp":1581482627000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Development of Obsessive-Compulsive Symptoms Following Abrupt Discontinuation of Venlafaxine"],"prefix":"10.3389","volume":"11","author":[{"given":"Maximilian","family":"Gahr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Hiemke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus Alexander","family":"K\u00f6lle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,2,12]]},"reference":[{"key":"B1","article-title":"Antidepressant withdrawal phenomena","volume":"19","author":"Dilsaver","year":"1984","journal-title":"Biol Psychiatry"},{"key":"B2","first-page":"5","article-title":"Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition","author":"Schatzberg","year":"1997","journal-title":"Discontinuation Consensus panel. J Clin Psychiatry"},{"key":"B3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0006-3223(98)00126-7","article-title":"Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized controlled trial","volume":"44","author":"Rosenbaum","year":"1998","journal-title":"Biol Psychiatry"},{"volume-title":"Diagnostic and Statistical Manual of Mental Disorder","year":"2013","key":"B4"},{"key":"B5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1159\/000370338","article-title":"Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review","volume":"84","author":"Fava","year":"2015","journal-title":"Psychother Psychosom"},{"key":"B6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1159\/000491524","article-title":"Withdrawal symptoms after serotonin-noradrenaline reuptake inhibitor discontinuation: systematic review","volume":"87","author":"Fava","year":"2018","journal-title":"Psychother Psychosom"},{"key":"B7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1159\/000371865","article-title":"New classification of selective serotonin reuptake inhibitor withdrawal","volume":"84","author":"Chouinard","year":"2015","journal-title":"Psychother Psychosom"},{"key":"B8","doi-asserted-by":"publisher","first-page":"E747","DOI":"10.1503\/cmaj.160991","article-title":"Antidepressant discontinuation syndrome","volume":"189","author":"Gabriel","year":"2017","journal-title":"CMAJ"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2018.08.027","article-title":"A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: are guidelines evidence-based","volume":"97","author":"Davies","year":"2019","journal-title":"Addict Behav"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4088\/PCC.14m01715","article-title":"Incidence and timing of taper\/posttherapy-emergent adverse events following discontinuation of desvenlafaxine 50 mg\/d in patients with major depressive disorder","author":"Ninan","year":"2015","journal-title":"Prim Care Companion CNS Disord"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32807fb1b2","article-title":"Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial","volume":"22","author":"Hartford","year":"2007","journal-title":"Int Clin Psychopharmacol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1159\/000078225","article-title":"A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder","volume":"50","author":"Montgomery","year":"2004","journal-title":"Neuropsychobiology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n1015","article-title":"Randomized trial of sertraline versus velafaxine XR in major depression: efficacy and discontinuation symptoms","volume":"66","author":"Sir","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/00004850-200609000-00008","article-title":"Escitalopram versus venlafaxine XR in the treatment of depression","volume":"21","author":"Montgomery","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1097\/YIC.0b013e32832fbb5a","article-title":"Discontinuation symptoms and taper\/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder","volume":"24","author":"Montgomery","year":"2009","journal-title":"Int Clin Psychopharmacol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31802e84b9","article-title":"Venlafaxine discontinuation syndrome and suicidal ideation: a case series","volume":"27","author":"Stone","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nrn3746","article-title":"Obsessive-compulsive disorder: an integrative genetic and neurobiological perspective","volume":"15","author":"Pauls","year":"2014","journal-title":"Nat Rev Neurosci"},{"key":"B18","first-page":"5","article-title":"Practice guideline for the treatment of patients with obsessive-compulsive disorder","volume":"164","author":"Koran","year":"2007","journal-title":"Am J Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(01)00298-6","article-title":"Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors","volume":"25","author":"Bymaster","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000023","article-title":"A comparative review of escitalopram, paroxetine, and sertraline: are they all alike","volume":"29","author":"Sanchez","year":"2014","journal-title":"Int Clin Psychopharmacol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1517\/13543784.6.1.65","article-title":"Venlafaxine: a novel antidepressant compound","volume":"6","author":"Schweizer","year":"1997","journal-title":"Expert Opin Invest Drugs"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200746040-00002","article-title":"The clinical pharmacokinetics of escitalopram","volume":"46","author":"Rao","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1159\/000488945","article-title":"What is new about new antidepressant","volume":"87","author":"Dubovsky","year":"2018","journal-title":"Psychother Psychosom"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000570","article-title":"Behavioral toxicity revisited: iatrogenic comorbidity in psychiatric evaluation and treatment","volume":"36","author":"Fava","year":"2016","journal-title":"J Clin Psychopharmacol"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fpsyt.2020.00032\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T04:43:50Z","timestamp":1581482630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fpsyt.2020.00032\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,12]]},"references-count":24,"alternative-id":["10.3389\/fpsyt.2020.00032"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2020.00032","relation":{},"ISSN":["1664-0640"],"issn-type":[{"type":"electronic","value":"1664-0640"}],"subject":[],"published":{"date-parts":[[2020,2,12]]},"article-number":"32"}}